The Impact of Diabetes on Cognitive Performance: A Comprehensive Review

Xudong Zhou

doi:10.62051/ijphmr.v3n1.02

Authors

Xudong Zhou

DOI:

https://doi.org/10.62051/ijphmr.v3n1.02

Keywords:

Diabetes, Cognitive Dysfunction, Neuroimaging Techniques, Glycemic Control, Therapeutic Interventions

Abstract

Diabetes Mellitus, a prevalent metabolic disorder, is increasingly acknowledged as a critical determinant of cognitive impairment. This comprehensive review synthesizes the current understanding of the pathophysiological mechanisms underlying cognitive deficits in diabetic individuals. It explores the contributions of chronic hyperglycemia, microvascular pathology, impaired insulin signaling, oxidative stress, and neuroinflammation as key drivers of neuronal injury and cognitive decline. And then the review delineates a range of risk factors—including advanced age, inadequate glycemic control, hypertension, and dyslipidemia—that exacerbate susceptibility to cognitive dysfunction in this patient population. The utility of advanced neuroimaging techniques and neuropsychological assessments in the detection and monitoring of cognitive changes is rigorously evaluated. Additionally, the article examines emerging preventive and therapeutic strategies, such as rigorous blood glucose control, management of cardiovascular risk factors, administration of antioxidants and anti-inflammatory agents, neuroprotective interventions, and psychological support. The review concludes with a discussion of its clinical relevance, underscoring the necessity for timely diagnosis and integrated management approaches to mitigate the cognitive burden of diabetes, and suggests avenues for future research aimed at addressing current knowledge voids and improving patient outcomes.

References

[1] Zhou, B. et al. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. The Lancet 404, 2077–2093 (2024).

[2] Choi, Y. et al. Association of Cardiovascular Health Score With Early-and Later-Onset Diabetes and With Subsequent Vascular Complications of Diabetes. Journal of the American Heart Association 12, e027558 (2023).

[3] Li, R. et al. Correlation of mild cognitive impairment with the thickness of retinal nerve fiber layer and serum indicators in type 2 diabetic patients. Front. Endocrinol. 14, 1299206 (2024).

[4] Biessels, G. J. & Whitmer, R. A. Cognitive dysfunction in diabetes: how to implement emerging guidelines. Diabetologia 63, 3–9 (2020).

[5] Zhou, X. et al. Subcutaneous device-free islet transplantation. Front. Immunol. 14, 1287182 (2023).

[6] Chen, W., Cai, W., Hoover, B. & Kahn, C. R. Insulin Action in the Brain: Cell Types, Circuits, and Diseases. TrendsNeurosc 45, 384–400 (2023).

[7] Hölscher, C. Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer’s Disease. Front. Aging Neurosci. 11, 88 (2019).

[8] Lee, J. C., Kim, S. J., Hong, S. & Kim, Y. Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med 51, 1–10 (2019).

[9] González, P., Lozano, P., Ros, G. & Solano, F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. IJMS 24, 9352 (2023).

[10] Matuschik, L. et al. Hyperglycemia Induces Inflammatory Response of Human Macrophages to CD163-Mediated Scavenging of Hemoglobin-Haptoglobin Complexes. IJMS 23, 1385 (2022).

[11] Bayaraa, O. et al. Hyperglycemic conditions induce rapid cell dysfunction-promoting transcriptional alterations in human aortic endothelial cells. Sci Rep 12, 20912 (2022).

[12] Ogoh, S. Relationship between cognitive function and regulation of cerebral blood flow. J Physiol Sci 67, 345–351 (2017).

[13] Rungratanawanich, W., Qu, Y., Wang, X., Essa, M. M. & Song, B.-J. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med 53, 168–188 (2021).

[14] Liberty, I. A. et al. The characteristics and risk of obesity central and concomitant impaired fasting glucose: Findings from a cross-sectional study. PLoS ONE 19, e0305604 (2024).

[15] Ottoy, J. et al. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. NeuroImage: Clinical 22, 101771 (2019).

[16] Yue, Q. & Hoi, M. P. M. Emerging roles of astrocytes in blood-brain barrier disruption upon amyloid-beta insults in Alzheimer’s. NEURAL REGENERATION RESEARCH 18, 1890–1902 (2023).

[17] Yong, S. et al. The effect and mechanism of palmar ginseng in type 2 diabetic cognitive impairment. Heliyon 10, e32525 (2024).

[18] You, Y. et al. The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Acta Diabetol 58, 671–685 (2021).

[19] Aderinto, N. et al. The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations. Medicine 102, e35557 (2023).

[20] Dv, D. Blood pressure control for diabetic retinopathy (Review). Cochrane Database of Systematic Reviews 3, CD006127 (2023).